Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.11
  • Today's Change-0.26 / -1.50%
  • Shares traded7.40m
  • 1 Year change+97.12%
  • Beta0.8074
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,2262,8012,165
Total Receivables, Net3,4083,6964,529
Total Inventory4,0223,8333,818
Prepaid expenses1,2551,1621,075
Other current assets, total575559986
Total current assets12,48612,05112,573
Property, plant & equipment, net6,1476,1586,477
Goodwill, net17,17717,63320,040
Intangibles, net5,3876,2707,466
Long term investments------
Note receivable - long term------
Other long term assets471441514
Total assets43,48044,01147,666
LIABILITIES
Accounts payable2,6021,8871,686
Accrued expenses3,4792,8102,880
Notes payable/short-term debt232323
Current portion long-term debt/capital leases1,6492,0861,403
Other current liabilities, total4,4944,6635,035
Total current liabilities12,24711,46911,027
Total long term debt18,16119,10321,617
Total debt19,83321,21223,043
Deferred income tax606548784
Minority interest620794966
Other liabilities, total4,3394,2932,994
Total liabilities35,97336,20737,388
SHAREHOLDERS EQUITY
Common stock575757
Additional paid-in capital27,80727,68827,561
Retained earnings (accumulated deficit)(13534)(12975)(10529)
Treasury stock - common(4128)(4128)(4128)
Unrealized gain (loss)----0
Other equity, total(2696)(2838)(2683)
Total equity7,5067,80410,278
Total liabilities & shareholders' equity43,47944,01147,666
Total common shares outstanding1,1211,1211,103
Treasury shares - common primary issue106106106
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.